Table 3.

Extrapolations based on the latest case counts using the base rates from Taquet et al [9] of first presentation of neurological and neuropsychiatric outcomes after SARS-CoV-2 infection for select regions/countries.^a

Neurological and psychiatric outcomes	Base rates (%) [9]	Case counts, n
		Worldb (N=198,336,258)	Germanyb (N=3,778,277)	Europec (N=34,435,890)	United Statesb (N=35,003,546)	Indiab (N=31,695,958)	Brazilb (N=19,938,358)
Neurological	2.10	4,165,061	79,344	723,154	735,074	665,615	418,706
Any psychiatric disorder (mood, anxiety, psychotic)	8.63	17,116,419	326,065	2,971,817	3,020,806	2,735,361	1,720,680
Substance misuse	1.92	3,808,056	72,543	661,169	672,068	608,562	382,816
Insomnia	2.53	5,017,907	95,590	871,228	885,590	801,908	504,440
Any first outcome	12.84	25,466,376	485,131	4,421,568	4,494,455	4,069,761	2,560,085

^aThis table is for illustrative purposes only and is neither exhaustive nor necessarily reflective of the future outcomes in any given country or region.

^bFrom the COVID-19 web-based dashboard of Johns Hopkins Coronavirus Resource Center accessed August 2, 2021 [11].

^cBased on the COVID-19 situation update for the European Union/European Economic Area as of July 30, 2021 [12].